|
|||||
|
|
| 初诊外周T细胞淋巴瘤治疗进展 | |
| 引用本文： | 赵林俊(综述),平凌燕(审校). 初诊外周T细胞淋巴瘤治疗进展[J]. 中国肿瘤临床, 2021, 48(2): 100-104. DOI: 10.3969/j.issn.1000-8179.2020.02.021 |
| 作者姓名： | 赵林俊(综述) 平凌燕(审校) |
| 作者单位： | 北京大学国际医院淋巴瘤科（北京市102206） |
| 摘 要： | 外周T细胞淋巴瘤(peripheral T-cell lymphoma,PTCL)为一组高度异质性的侵袭性非霍奇金淋巴瘤,整体预后差,目前一线治疗以CHOP(环磷酰胺+阿霉素+长春新碱+泼尼松)方案为主,但复发率较高,最近多项研究报道了初诊PTCL的治疗进展,主要涉及新的化疗方案的探索、新药联合治疗的尝试、自体干细胞移... |
| 关 键 词： | 淋巴瘤 T细胞 外周 初诊 治疗 |
| 收稿时间： | 2020-08-11 |
Advances in the treatment of newly diagnosed peripheral T-cell lymphoma |
|
| Affiliation: | Department of Lymphoma, Peking University International Hospital, Beijing 102206, China |
| Abstract: | Peripheral T-cell lymphomas(PTCLs)comprise a group of highly heterogeneous,aggressive non-Hodgkin's lymphomas with a poor overall prognosis.Currently,the first-line treatment for PTCL is the cyclophosphamide+doxorubicin+vincristine+prednisone(CHOP)regimen.However,the recurrence rate is still high.Recently,several studies have reported on the progress in first-line treatments for PTCL.These studies mainly involved the exploration of new chemotherapy regimens,trial of new drugs in combination with chemotherapy,trial of new drug combinations,and the application of autologous stem cell transplantation(ASCT).New therapeutic protocols are a source of hope to patients.Targeted therapy according to the new molecular classification may change the current treatment strategy.This article reviews the advancements in the treatment of newly diagnosed peripheral T-cell lymphoma. |
| Keywords: | lymphoma T-cell peripheral newly diagosed treatment |
| 本文献已被 维普 等数据库收录！ | |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 | |
| 点击此处可从《中国肿瘤临床》下载免费的PDF全文 | |